Aleniglipron: Side Effects

Safety Overview#

Aleniglipron demonstrated tolerability consistent with the GLP-1 agonist class in Phase 2b ACCESS. GI events were most common during titration. Discontinuation rates averaged 10.4% across active arms (range 7.7-13.3%).

GLP-1 Agonist Class Warnings#

Standard class warnings apply: thyroid C-cell tumors (rodent data), pancreatitis, gallbladder events, and GI adverse events.

Limitations#

Safety data from single Phase 2b trial. Long-term safety, rare adverse events, and drug interactions not fully characterized.

Safety Profile Context#

Aleniglipron belongs to the Metabolic category of research peptides. Understanding the side effect profile of Aleniglipron is essential for researchers designing clinical protocols and for healthcare providers advising patients. The side effects documented here are based on available clinical trial data and may not represent the complete safety profile.

Reported Side Effects#

The following side effects have been documented in clinical studies of Aleniglipron. Side effect severity and frequency are based on available clinical data.

Nausea#

Severity: mild | Frequency: common

Most common adverse event during dose titration. Consistent with GLP-1 receptor agonist class. Typically improves after titration.

Vomiting#

Severity: mild | Frequency: common

Reported during titration phase. Predominantly mild to moderate.

Contraindications#

The following contraindications have been identified for Aleniglipron based on available research and pharmacological considerations:

• Investigational compound: not approved for clinical use
• Expected class contraindications based on GLP-1 receptor agonist class

Individuals with any of these conditions should not use Aleniglipron without consulting a qualified healthcare provider.

Drug Interactions#

The following potential drug interactions have been identified for Aleniglipron:

• Drug interactions not fully characterized. Based on GLP-1 class, delayed gastric emptying may affect oral drug absorption. CYP interactions may need evaluation as a small molecule.

Drug interaction studies for Aleniglipron remain limited. Researchers should exercise caution when combining Aleniglipron with other compounds and consult relevant pharmacological references.

Related Reading#

• Aleniglipron overview and research guide
• Aleniglipron dosing protocols
• Aleniglipron risks and legal status